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recruited to date, and two have been infused with VSTs at
5x10E6 cells/m2/dose. The manufactured VSTs had a CD4+ T-
cell predominance with detectable antiviral activity against
CMV pp65/IE1, EBV-LMP2/EBNA1, and Adv-Hexon/Penton
epitopes based on IFN-g ELISpot assays. All VSTs were non-
alloreactive in chromium release assays utilizing allogeneic
PHA blasts as targets (<5% lysis at effector:target ratios of
20:1). The ﬁrst patient was treated for CMV viremia which
was refractory to ganciclovir and foscarnet following hap-
loidentical HSCT for SCID. Following two VST infusions, the
CMV load reduced from >1,000,000 to<1000 copies/ml. The
second patient was treated for CMV viremia after matched
sibling HSCT for MHC-II deﬁciency, and had viral clearance of
CMV within 1-month post-VST infusion. One patient devel-
oped Grade I skin GVHD post VSTs which resolved within 1
week and was associated with the tapering of immune
suppression.
Conclusions: VSTs are safe and effective for control of viral
infections in patients with PIDD following HSCT. We plan
further evaluation of virus-speciﬁc CTL for patients with
PIDD both before and after HSCT.309
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Background: Inherited bone marrow failure syndromes
(IBMFS) include genetic disorders with hematopoietic
cytopenias due to mutations in genes supporting normal
hematopoiesis. Transformation to myeloid leukemia or
myelodysplastic syndrome occurs in 4-25% by adulthood.
Allogeneic hematopoietic cell transplantation (HCT) is cura-
tive but has been largely limited to sibling donor HCT due to
toxicities of alternative donor transplants. The development
of successful HCT strategies is necessary in this setting to
beneﬁt more patients. This includes optimizing transplant
conditioning, reducing mortality, late effects, and GVHD so
HCT can beneﬁt more patients.
Hypothesis: A reduced intensity conditioning regimen (RIC)
and HCT from matched marrow or matched/one-antigen
mismatched cord will result in high overall survival (OS) and
event-free survival (EFS) in patients (<21 years) with IBMFS
(excluding Fanconi Anemia).
Methods: IBMFS patients (3 Diamond-Blackfan Anemia,
1 Congenital Dyserythropoietic Anemia, 1 Shwachman-
Diamond Syndrome, 2 Congenital Amegakaryocytic
Thrombocytopenia, 1 Congenital BM Failure, 1 X-linked
Thrombocytopenia, 1 Severe Congenital Neutropenia, 1 X-
Chromosome Deletion) received alemtuzumab intrave-
nously for 3 days (dose 33 mg if <10kg; 45 mg if >10kg)
(day -21 to -19), ﬂudarabine (30 mg/m2/day) (day -8 to -4)
and melphalan (140 mg/m2) on day -3. All received acalcineurin inhibitor as GVHD prophylaxis. Marrow re-
cipients received short course methotrexate and steroids,
and cord recipients received mycophenolate.
Results: Eleven patients between 2 months and 14 years of
age (median 23 months) underwent HCT. Nine were from
unrelated donors; ten received BM; one received UCB. Ten
had full donor chimerism by 30 days. OS and EFS were 82%
with median follow up of 62 months (range 12-186). Two
deaths (BM recipients for DBA and Congenital BMF) at day 45
and 346 were due to aGVHD and graft rejection followed by
mortality after a second transplant respectively. The cumu-
lative incidence of acute (grade II-IV) and chronic GVHD was
9 and 0% respectively. Eight of the 9 survivors had success-
fully discontinued systemic immunosuppression by one year
post HCT. Robust immune reconstitution was noted at 1 year
in survivors.
Conclusions: This RIC regimen was tolerated well by this
very young recipient group. The regimen had a high success
rate (also previously described in HCT for Shwachman-Dia-
mond syndrome: Bhatla, BMT 2008) and is expected to have
fewer late toxicities. Though the numbers are small, out-
comes are encouraging in these rare disorders supporting a
HCT consideration early during the course of the disease
prior to marrow related complications.310
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Overview: BK viremia (BKV) occurs in >15% of patients after
hematopoietic cell transplantation (HCT), primarily in asso-
ciation with cystitis. It is unknown if BK virus-induced renal
disease (polyomavirus nephropathy, PVN) is also common
after HCT. Kidney biopsy is the gold standard for the diag-
nosis of PVN but has a high risk of bleeding after HCT. The
non-invasive urinary PV-Haufen test is sensitive/speciﬁc for
PVN in renal transplant recipients with positive/negative
predictive values >90%. PV-Haufen are cast-like BK aggre-
gates that form in virally injured kidney tubules, are shed,
and can easily be detected in urine samples. PV-Haufen do
not form in the bladder and are not seen in cystitis without
PVN. In this pilot study, we used the PV-Haufen test for the
ﬁrst time in children after HCT to screen for PVN.
Methods: Subjects with BKV (potential cases) and without
BKV (presumed controls) after allogeneic HCT were selected
from cohorts at Cincinnati Children’s Hospital and the Chil-
dren’s Hospital of Philadelphia. Urine samples (10-25 ml)
were ﬁxed in a 1:1 ratio with 4% paraformaldehyde, stored at
4C, and tested for urinary PV-Haufen using negative staining
electron microscopy (JASN, 2009, 20(2):416-27). Urine sam-
ples containing 1 PV-Haufen were classiﬁed as positive,
supporting a diagnosis of PVN.
Results:We tested 20 voided urine samples from 15 subjects
(median age 11.5 years, range 5.2-29.8; median HCT follow
up time 306 days, range 87-815). Urine Haufen (Fig 1) were
